Idaho Technology, Inc., today announced it has changed the corporate name to BioFire Diagnostics, Inc. to more accurately reflect its business strategy and strong momentum in the marketplace. The Company has also re-launched its website.
"We are excited to announce our new name to our customers and industry members," said Kirk Ririe, Chief Executive Officer of BioFire Diagnostics. "The new name reflects the passion and energy of the Company and management team, and highlights our expanded presence in the clinical diagnostics market.
"We have established strong momentum in the diagnostics marketplace and the new branding under BioFire Diagnostics better reflects the markets we serve. We believe we are in an excellent position to continue building our business by driving growth of our broad molecular diagnostic product portfolio."
BioFire Diagnostics will continue to focus on leveraging its novel FilmArray® pathogen detection system to develop multiplex diagnostic tests for various clinical applications. The FilmArray Respiratory Panel (RP) is FDA-cleared for 20 viral and bacterial respiratory pathogens. BioFire now provides the only FDA cleared clinical diagnostic test for eight of the 20 organisms in its panel. In addition to the FilmArray RP, the Company is developing similar FilmArray panels for pathogen identification in blood culture, gastrointestinal infections, meningitis and much more.
In addition to its enthusiasm around the clinical diagnostics space, BioFire will continue to lead in the development of reliable and sensitive biosurveillance products such as its PCR-based biodetection system RAZOR® EX and the FilmArray BioSurveillance System.